Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Heron Therapeutics (HRTX) Shares Outstanding (2016 - 2025)

Heron Therapeutics' Shares Outstanding history spans 13 years, with the latest figure at $188.3 million for Q4 2025.

  • For Q4 2025, Shares Outstanding rose 23.79% year-over-year to $188.3 million; the TTM value through Dec 2025 reached $188.3 million, up 23.79%, while the annual FY2025 figure was $188.3 million, 23.79% up from the prior year.
  • Shares Outstanding reached $188.3 million in Q4 2025 per HRTX's latest filing, up from $183.3 million in the prior quarter.
  • In the past five years, Shares Outstanding ranged from a high of $188.3 million in Q4 2025 to a low of $91.4 million in Q1 2021.
  • Average Shares Outstanding over 5 years is $132.7 million, with a median of $130.5 million recorded in 2023.
  • Peak YoY movement for Shares Outstanding: grew 26.36% in 2024, then crashed 99.65% in 2025.
  • A 5-year view of Shares Outstanding shows it stood at $102.0 million in 2021, then increased by 16.81% to $119.2 million in 2022, then rose by 26.13% to $150.3 million in 2023, then increased by 1.23% to $152.1 million in 2024, then rose by 23.79% to $188.3 million in 2025.
  • Per Business Quant, the three most recent readings for HRTX's Shares Outstanding are $188.3 million (Q4 2025), $524000.0 (Q3 2025), and $153.3 million (Q2 2025).